Evidence map›Paper›PMID 30023346›Full record

ArticleEuropean thyroid journal2018

Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction.

Satoshi Koyama, Naritomo Miyake, Kazunori Fujiwara, Tsuyoshi Morisaki, Takahiro Fukuhara, Hiroya Kitano, Hiromi Takeuchi

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European thyroid journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Multikinase Inhibitor Treatment in Thyroid Cancer.International journal of molecular sciences · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Satoshi KoyamaDepartment of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan.
Naritomo MiyakeDepartment of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan.
Kazunori FujiwaraDepartment of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan.
Tsuyoshi MorisakiDepartment of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan.
Takahiro FukuharaDepartment of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan.
Hiroya KitanoDepartment of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan.
Hiromi TakeuchiDepartment of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan.
Tottori University · JPTokatsu Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLenvatinib is an oral multitargeted tyrosine kinase inhibitor that has an anticancer action in patients with differentiated thyroid cancer that is refractory to radioiodine. Knowledge of the efficacy and safety of lenvatinib in patients with anaplastic thyroid cancer (ATC) is limited. Tyrosine kinase inhibitors frequently cause hypothyroidism, but the incidence of hypothyroidism with lenvatinib is unclear.

objectivesWe conducted a retrospective study to investigate the efficacy and safety of lenvatinib in ATC.

methodsFive patients with unresectable ATC were enrolled. Lenvatinib 24 mg once daily was administered until disease progression, unmanageable toxicity, withdrawal, or death occurred. We retrospectively analyzed the objective response rate (ORR), time to progression (TTP), overall survival, and safety.

resultsThree of the 5 patients (60%) had a partial response, and 5 (40%) had stable disease. The ORR was 60%. Median TTP was 88 days, and overall survival was 165 days. Hypothyroidism was a common treatment-related adverse effect; 4 patients (80%) had hypothyroidism of any grade. These 4 patients had not undergone total thyroidectomy prior to lenvatinib administration, and the other patient had undergone total thyroidectomy. Treatment-related adverse effects of any grade were hypertension in 80% of patients, diarrhea in 40%, fatigue in 80%, and decreased appetite in 80%.

conclusionsLenvatinib is an effective treatment and may improve the prognosis of unresectable ATC. Four of the 5 patients had hypothyroidism, which may have been associated with treatment-induced injury of the thyroid gland. There were many treatment-related adverse effects, most of which were manageable by dose modification and medical therapy.

Indexed as

Anaplastic thyroid cancerChemotherapyHypothyroidismLenvatinibTyrosine kinase inhibitor

Identifiers

PMID30023346
PMCPMC6047489
OpenAlexW2788162170

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.